Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 43.63% from the stock’s previous close. A […]

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock. Separately, StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, […]

HC Wainwright restated their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a research note released on Thursday, Benzinga reports. They currently have a $37.00 price target on the stock. Pharming Group Price Performance Shares of NASDAQ PHAR opened at $8.49 on Thursday. The firm has a market cap of $575.88 […]

HC Wainwright reaffirmed their neutral rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note published on Thursday, Benzinga reports. Separately, StockNews.com cut DURECT from a hold rating to a sell rating in a research note on Thursday, August 8th. View Our Latest Stock Analysis on DURECT DURECT Price Performance Shares of […]

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 265.85% from the stock’s previous close. Separately, […]

HC Wainwright restated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) in a report released on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. Several other analysts have also recently issued reports on BRNS. William Blair reaffirmed an outperform rating on shares of Barinthus Biotherapeutics in […]

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target cut by analysts at HC Wainwright from $23.00 to $18.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 28.48% from the […]